Drug metyrapone shows promise for Cushing's patients who Can't have surgery

NCT ID NCT05255900

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug metyrapone in 20 people with mild Cushing's syndrome who were not candidates for surgery. Over 24 weeks, researchers measured changes in blood pressure, blood sugar, cholesterol, bone health, and mental health. The goal was to see if metyrapone could help control these problems caused by high cortisol levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

metyrapone

What this could lead to

If successful, metyrapone could become a treatment option for patients with mild Cushing's syndrome who cannot have surgery, helping control blood pressure and blood sugar.

What could go wrong

This is a small, completed study with only 20 participants, so results may not apply to everyone. Metyrapone can cause side effects like nausea or low blood pressure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCORTISOLISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cushing syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Istituto Auxologico Italiano

    Milan, 20149, Italy